Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003473 · ClinicalTrials.gov registry record · Phase 2
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
A Phase 2 study, sponsored by Burzynski Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00003473 is a Phase 2 study that has completed, run by Burzynski Research Institute. The registered enrollment target is 20 participants.
The verdict
NCT00003473, a Phase 2 study, has completed, sponsored by Burzynski Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
RATIONALE: Current therapies for adults with recurrent or refractory mixed gliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with recurrent or refractory mixed gliomas. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with recurrent or refractory mixed gliomas.
Interventions
- DRUG Atengenal
- DRUG Astugenal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1996-03 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003473
The ClinicalTrials.gov registry entry for NCT00003473 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Burzynski Research Institute, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atengenal is the first listed.
NCT00003473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003473 about?
NCT00003473 is a clinical study titled "Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas". RATIONALE: Current therapies for adults with recurrent or refractory mixed gliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with recurrent or refractory mixed gliomas. PURPOSE: T...
What is the current status of trial NCT00003473?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 1996-03. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00003473?
The interventions under investigation include: Atengenal (DRUG), Astugenal (DRUG).
Who is sponsoring clinical trial NCT00003473?
This trial is sponsored by Burzynski Research Institute, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.